Markers of PI3K/Akt, ER & AR pathways and Ki67 expression in relation to tamoxifen outcome in ER plus breast cancer

被引：0
|
作者：
Campbell, C.
Mathew, J.
Ellis, I.
Finlay, P.
Green, A.
Bradbury, I.
Borgquist, S.
Elebro, K.
Politz, O.
Haegebarth, A.
Gee, J. M.
Robertson, J. F.
机构：
[1] Frontier Sci Scotland, Inverness, Scotland
[2] Peterborough City Hosp, Peterborough, Cambs, England
[3] Nottingham Univ Hosp, Nottingham, England
[4] Cardiff Univ, Cardiff, S Glam, Wales
[5] Aarhus Univ, Aarhus, Denmark
[6] Skane Univ Hosp, Malmo, Sweden
[7] Bayer, Berlin, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P2-03-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Drugging the PI3K/AKT/mTOR Pathway in ER plus Breast Cancer
    Alves, Carla L.
    Ditzel, Henrik J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [2] PI3K inhibitors in ER plus breast cancer: Next steps
    Ellis, Matthew J.
    Crowder, Robert
    Ma, Cynthia X.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [3] CLA reduces breast cancer cell growth and invasion through ERα and PI3K/Akt pathways
    Bocca, C.
    Bozzo, F.
    Cannito, S.
    Colombatto, S.
    Miglietta, A.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2010, 183 (01) : 187 - 193
  • [4] ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
    Lin, Sheng-Li
    Yan, Li-Ying
    Zhang, Xin-Tian
    Yuan, Ju
    Li, Mo
    Qiao, Jie
    Wang, Zhao-Yi
    Sun, Qing-Yuan
    PLOS ONE, 2010, 5 (02):
  • [5] Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression
    Heber, Ulrike
    Tendl-Schulz, Kristina
    Heber, Stefan
    Danzinger, Sabine
    Bartsch, Rupert
    Singer, Christian F.
    Fitzal, Florian
    Exner, Ruth
    Gnant, Michael F.
    Mullauer, Leonhard
    Bago-Horvath, Zsuzsanna
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Cystatin SN Affects Cell Proliferation by Regulating the ERα/PI3K/AKT/ERα Loopback Pathway in Breast Cancer
    Liu, Yanfang
    Ma, Hong
    Wang, Ye
    Du, Xinyang
    Yao, Jing
    ONCOTARGETS AND THERAPY, 2019, 12 : 11359 - 11369
  • [7] Autophagy promotes escape from PI3K inhibition in ER plus breast cancer
    Yang, Wei
    Miller, Todd W.
    CANCER RESEARCH, 2015, 75
  • [8] Ketogenic diet and letrozole to inhibit PI3K signaling in ER plus breast cancer
    Rexer, Brent
    Abramson, Vandana
    Nunnery, Sara
    Reid, Sonya
    Kennedy, Laura
    Sanders, Melinda
    Bennett, Jessica
    Gonzalez-Ericsson, Paula
    Sanchez, Violeta
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Pharmacodynamics and consequences of PI3K inhibition in ER plus breast tumors
    Yang, W.
    Bean, J.
    Hosford, S.
    Lloye, D.
    Liu, S.
    Salphati, L.
    Pang, J.
    Zhang, X.
    Nannini, M.
    Miller, T. W.
    CANCER RESEARCH, 2016, 76
  • [10] Immunohistochemical Markers Progesterone Receptor, HER2, Ki67 and bcl-2-Associated Athanogene 1 and Prediction of Adjuvant Tamoxifen Treatment Outcome in ER plus Early Breast Cancer
    Gee, J. M.
    Aleskandarany, M. A.
    Finlay, P.
    Farrow, L.
    Nicholson, R. I.
    Habashy, H. O.
    Green, A. R.
    Rakha, E. A.
    Powe, D. G.
    Jasani, B.
    Barrett-Lee, P. J.
    Robertson, J. F.
    Shaw, V. E.
    Ellis, I. O.
    CANCER RESEARCH, 2010, 70
12345